共 50 条
- [41] Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialLANCET ONCOLOGY, 2022, 23 (06): : 739 - 747Wang, JieZhou, CaicunYao, WenxiuWang, QimingMin, XuhongChen, GongyanXu, XingxiangLi, XingyaXu, FeiFang, YongYang, RunxiangYu, GuohuaGong, YoulingZhao, JunFan, YunLiu, QuanCao, LejieYao, YuLiu, YunpengLi, XiaolingWu, JingxunHe, ZhiyongLu, KaihuaJiang, LiyanHu, ChengpingZhao, WenhuaZhang, BenShi, WeiZhang, XiaojingCheng, Ying
- [42] PATIENT-REPORTED OUTCOMES FROM THE LUME-LUNG 1 TRIAL: A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY IN SECOND-LINE ADVANCED NSCLC PATIENTSJOURNAL OF THORACIC ONCOLOGY, 2014, 9 (09) : S152 - S153Mellemgaard, AndersDouillard, Jean-YvesNovello, SilviaKaiser, RolfOrlov, SergeyKrzakowski, MaciejVon Pawel, JoachimGottfried, MayaBondarenko, IgorLiao, MeilinBarrueco, JoseGaschler-Markefski, BirgitGriebsch, IngolfReck, Martin
- [43] Effect of Calcium and Vitamin D Supplements as an Adjuvant Therapy to Metformin on Menstrual Cycle Abnormalities, Hormonal Profile, and IGF-1 System in Polycystic Ovary Syndrome Patients: A Randomized, Placebo-Controlled Clinical TrialADVANCES IN PHARMACOLOGICAL SCIENCES, 2019, 2019Kadoura, SallyAlhalabi, MarwanNattouf, Abdul Hakim
- [44] ESCORT-1st: A randomized, double-blind, placebo-controlled, phase 3 trial of camrelizumab plus chemotherapy versus chemotherapy in patients with untreated advanced or metastatic esophageal squamous cell carcinoma (ESCC).JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Xu, Rui-huaLuo, HuiyanLu, JinBai, YuxianMao, TengWang, JunFan, QingxiaZhang, YipingZhao, KuaileChen, ZhendongGao, SheganLi, JianchengFu, ZhichaoGu, KangshengLiu, ZhihuaWu, LinZhang, XiaodongZhu, YiYang, QingZou, Jianjun
- [45] Comparison of a Chinese Herbal Medicine (CCH1) and Lactulose as First-Line Treatment of Constipation in Long-Term Care: A Randomized, Double-Blind, Double-Dummy, and Placebo-Controlled TrialEVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2012, 2012Huang, Chien-HsunLin, Jui-ShanLi, Tsai-ChungLee, Shih-ChangWang, Hsiu PoLue, Hung-ChiSu, Yi-Chang
- [46] Repurposing bromocriptine for Aβ metabolism in Alzheimer's disease (REBRAnD) study: randomised placebo-controlled double-blind comparative trial and open-label extension trial to investigate the safety and efficacy of bromocriptine in Alzheimer's disease with presenilin 1 (PSEN1) mutationsBMJ OPEN, 2021, 11 (06):Kondo, TakayukiBanno, HaruhikoOkunomiya, TaroAmino, YokoEndo, KayokoNakakura, AkiyoshiUozumi, RyujiKinoshita, AkemiTada, HarueMorita, SatoshiIshikawa, HidehiroShindo, AkihiroYasuda, KenTaruno, YosukeMaki, TakakuniSuehiro, TakashiMori, KohjiIkeda, ManabuFujita, KojiIzumi, YuishinKanemaru, KazutomiIshii, KenjiShigenobu, KazueKutoku, YumikoSunada, YoshihideKawakatsu, ShinobuShiota, ShunjiWatanabe, ToshifumiUchikawa, OsamuTakahashi, RyosukeTomimoto, HidekazuInoue, Haruhisa
- [47] Evaluating neuroprotective agents for clinical anti-ischemic benefit using neurological and neuropsychological changes after cardiac surgery under cardiopulmonary bypass - Methodological strategies and results of a double-blind, placebo-controlled trial of GM(1) gangliosideSTROKE, 1996, 27 (05) : 858 - 874Grieco, GdHollosy, MCulliford, ATJonas, S
- [48] Bevacizumab (BV) maintenance therapy significantly delays disease progression (PD) or death compared with placebo (PL) in the AVADO trial (BV plus docetaxel [D] vs D + PL in 1st-line HER2-negative locally recurrent [LR] or metastatic breast cancer [mBC])CANCER RESEARCH, 2009, 69 (02) : 104S - 104SFumoleau, P.Greil, R.Rayson, D.Mueller, VBarni, S.Aleknavicius, E.Tellez, E.Wilson, C.Miles, D. W.
- [49] RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC)JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)Robert, N. J.Dieras, V.Glaspy, J.Brufsky, A.Bondarenko, I.Lipatov, O.Perez, E.Yardley, D.Zhou, X.Phan, S.
- [50] Phase 3, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and paclitaxel as first-line therapy in women with HER2+advanced breast cancer: BOLERO-1CANCER RESEARCH, 2015, 75Hurvitz, Sara A.Andre, FabriceJiang, ZefeiShao, ZhiminNeciosup, Silvia P.Mano, Max S.Tseng, Ling-MinZhang, QingyuanShen, KunweiLiu, DonggengDreosti, Lydia M.Feng, JifengBurris, Howard A.Toi, MasakazuBuyse, Marc E.Cabaribere, DavidLindsay, Mary-AnnKunz, TiffanyRao, ShanthaPacaud, Lida B.Taran, TetianaSlamon, Dennis